Johnson & Johnson Raises Forecast

Johnson & Johnson Raises Forecast

Research  these Stocks on Kapitall’s Playground Now

 
research now

Johnson & Johnson (JNJ) raised their full-year earnings forecast after quarterly profit increased from revenue from new drugs and the divestiture of an older drug. The older drug sold was Bystolic, a hypertension treatment, to Forest Laboratories Inc., and provided $357 million in cash, according to Bloomberg. (STAY AHEAD OF THE CURVE: Follow Kapitall on Twitter)

“The medical device and pharmaceutical units look good and are improving, which are two legs of the stool,” said Matt Miksic of Piper Jaffray & Co., but that the consumer is the missing leg. Sales fell 2.4% from a recall of an over-the-counter drug, which resulted in the shutdown of a Pennsylvania factory. He continued, “It’s very difficult to predict how long it will last and how much the company will have to spend.”

J&J CFO Dominic J. Caruso said that it is taking longer to return the recalled products to the shelves, and that half will be returned this year and the other half in 2013. In addition to the recall troubles, J&J was fined more than $1.1 billion after a jury found the company guilty of illegally marketing and misleading doctors about the antipsychotic medication Risperdal.

Despite the troubles that it faces, the company is still positive on its outlook.

Business Section: Investing Ideas

J&J has been afflicted with a few troubles, but could still continue to grow their revenues this year. Below is a list of drug companies that have seen institutional purchases over the current quarter. Do you think the smart money sees the same growth in these names?

List sorted by market cap.

 

Interactive Chart: Use the Compar-O-Matic to compare analyst ratings for the stocks mentioned below:

“1. Pacira Pharmaceuticals Inc. (PCRX, Earnings, Analysts, Financials): Engages in the development, commercialization, and manufacture of pharmaceutical products for hospitals and ambulatory surgery centers. Market cap at $312.77M. Net institutional purchases in the current quarter at 6.5M shares, which represents about 49.06% of the company's float of 13.25M shares.

 

“2. Ardea Biosciences, Inc. (RDEA, Earnings, Analysts, Financials): Focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Market cap at $758.73M. Net institutional purchases in the current quarter at 3.7M shares, which represents about 16.97% of the company's float of 21.80M shares.

 

“3. Dynavax Technologies Corporation (DVAX, Earnings, Analysts, Financials): A clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Market cap at $760.40M. Net institutional purchases in the current quarter at 34.7M shares, which represents about 25.24% of the company's float of 137.49M shares.

 

“4. Isis Pharmaceuticals, Inc. (ISIS, Earnings, Analysts, Financials): Engages in the discovery and development of antisense drugs using antisense drug discovery platform. Market cap at $746.19M. Net institutional purchases in the current quarter at 3.6M shares, which represents about 3.82% of the company's float of 94.19M shares.

 

“5. Sucampo Pharmaceuticals, Inc. (SCMP, Earnings, Analysts, Financials): Focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. Market cap at $346.09M. Net institutional purchases in the current quarter at 1.5M shares, which represents about 11.77% of the company's float of 12.74M shares.

 

“6. DepoMed Inc. (DEPO, Earnings, Analysts, Financials): Develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. Market cap at $349.79M. Net institutional purchases in the current quarter at 2.6M shares, which represents about 5.52% of the company's float of 47.13M shares.

 

“7. Pharmacyclics Inc. (PCYC, Earnings, Analysts, Financials): Operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Market cap at $1.78B. Net institutional purchases in the current quarter at 3.5M shares, which represents about 6.45% of the company's float of 54.27M shares.

 

“8. Cubist Pharmaceuticals Inc. (CBST, Earnings, Analysts, Financials): Operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Market cap at $2.53B. Net institutional purchases in the current quarter at 4.8M shares, which represents about 7.66% of the company's float of 62.68M shares.

 

“9. Par Pharmaceutical Companies Inc. (PRX, Earnings, Analysts, Financials): Through its subsidiary, Par Pharmaceutical, Inc. engages in the development, manufacture, and distribution of generic and branded drugs in the United States. Market cap at $1.49B. Net institutional purchases in the current quarter at 1.1M shares, which represents about 3.08% of the company's float of 35.68M shares.

 

“10. Sagent Pharmaceuticals, Inc. (SGNT, Earnings, Analysts, Financials): Engages in developing, manufacturing, sourcing, and marketing pharmaceutical products, principally injectable-based generic equivalents primarily in the United States. Market cap at $507.97M. Net institutional purchases in the current quarter at 1.5M shares, which represents about 8.25% of the company's float of 18.19M shares.

 

 

(Written by Danny Guttridge)

 

Use Kapitall's Tools: Looking for ways to analyze this list?

Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall's tab navigation to browse through the data…

 

Analyze These Ideas: Getting Started

Dig Deeper: Access Company Snapshots, Charts, Filings

New to Kapitall?

1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter

 

 

 

playthemarket640jpg

Leave a Reply

Protected by WP Anti Spam

playthemarket280jpg
  • See Most Recent Articles